×

Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015

BOSTON, July 28, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, August 5, 2015 at 8:00 a.m. ET to discuss its second quarter 2015 financial results and provide a review of the Auryxia™ launch.

In order to participate in the conference call, please call 1-888-396-2320 (U.S.), 1-(774)-264-7560 (international) and refer to conference ID: KERYX. The call will also be webcast with slides and accessible through the Investors section of the company's website at www.keryx.com. The audio replay will be available at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for people with renal disease. In December 2014, the Company launched its first FDA-approved medicine, Auryxia™ (ferric citrate) for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In July 2015, the CHMP of the European Medicines Agency recommended granting a market authorization for Fexeric® (ferric citrate coordination complex) for the treatment of hyperphosphatemia in adults with chronic kidney disease. For more information about Keryx, please visit www.keryx.com.

CONTACT: Keryx Contact: Lora Pike Senior Director, Investor Relations T: 617.466.3511 lora.pike@keryx.com

Source:Keryx Biopharmaceuticals, Inc.